Transaction · 0001193125-26-447915

Crystal Adam

Crystal Adam, PRES, R, D, reported an open-market or private sale at Tango Therapeutics, Inc. involving 1100.000000 shares for an estimated $25287.02. Reported holdings after the transaction were 115743.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, R, D
TNGXTango Therapeutics, Inc.
Trade date
Nov 02, 2026
Filing date
Nov 05, 2026
View on SEC Insider profile
Disclosed value-$25.2kShares × reported price
Shares traded1.10k$22.99 per share
Holdings after115kDirect
% of reported position traded0.94%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 116,843 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TNGX price since this filing

Daily closing prices, with the filing date and available return windows
TNGX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +0.3%1w ago -4.2%1d ago -1.9%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-447915
Common Stock
Transaction date
Nov 02, 2026
Filed Nov 05, 2026, 12:35 AM · 3d delay
Shares
1,100 sh
$22.99 per share
Estimated value
-$25.2k
Computed from shares × price
Holdings after
115,743 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, R&D

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.

  2. F2

    Represents the weighted average sales price per share. The shares sold at prices ranging from $21.83 to $22.8299 per share. Full information regarding the number of shares sold at each price shall be…

  3. F3

    Represents the weighted average sales price per share. The shares sold at prices ranging from $22.84 to $23.8399 per share. Full information regarding the number of shares sold at each price shall be…

  4. F4

    This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Original filing · 0001193125-26-447915
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TNGX